PHARMACEUTICAL/PBM PROMOTIONS TO MANAGED CARE: IMPACT ON FDA REGULATION, INDEPENDENCE IN FORMULARY DECISION-MAKING WILL BE TOPICS OF PUBLIC MEETING
Executive Summary
FDA wants to assess the knowledge and sophistication of managed care buyers to help the agency revise its role in regulation of drug promotional activities. FDA is asking specifically for information on the sophistication of the managed care market in the proposed agenda for an open meeting on promotional issues scheduled for Oct. 19-20.